Opportunities in the human vaccines market include leveraging innovations like mRNA technology to enhance vaccine efficacy and safety. Rising global health awareness and demand in emerging markets, ...

RNA vaccine technology has emerged as a groundbreaking approach in the field of immunology and infectious disease prevention.

Raina Biosciences published data from its generative AI platform in a study, “Deep generative models design mRNA sequences with enhanced translational capacity and stability,” recently published in ...

In the fast-evolving field of medical science, a new artificial intelligence model may be about to change the way mRNA-based drugs and vaccines are designed. Developed through a collaboration between ...

MIT engineers have successfully used a machine-learning model to design nanoparticles that can deliver RNA to cells more efficiently. Using artificial intelligence, MIT researchers have come up with a ...

Federal funding cuts to vaccine research have impacted scientists nationwide — and some of those cuts hit close to home.

We recently published 11 Best Cancer Stocks to Buy Right Now. Moderna, Inc. stands fifth among them. Moderna, Inc. (NASDAQ:MRNA) stands fifth among the best cancer stocks. It is best known for its ...

The MarketWatch News Department was not involved in the creation of this content. -- GEMORNA is world's first generative AI platform purpose-built for mRNA design and optimization, demonstrating state ...

– GEMORNA is world’s first generative AI platform purpose-built for mRNA design and optimization, demonstrating state-of-the-art performance across diverse mRNA therapeutic applications – – GEMORNA ...

CAMBRIDGE, Mass., August 28, 2025 – Raina Biosciences Inc., (“Raina”), an mRNA technology and therapeutics company, today announced the publication of data from its generative AI platform in Science.